On May 9, 2024, significant advancements were made in the Ozempic multidistrict litigation (MDL), currently underway in Philadelphia
In addition to directly influencing satiety and appetite control via hypothalamic and hindbrain pathways, GLP-1RAs appear to engage higher-order networks involved in reward processing and emotional regulation, such as the insula, amygdala, and medial prefrontal cortex
My entire body is sore after class
Moreover, this approach works fast, has little downtime, and can be tailored for every individual, so its perfect for those who wish to modify the form of their body without surgery
Available from Accessed June 2025 Trinh D, McDonald M (2024) Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: Environmental Scan
This month's Broker Brief breaks down: - Why up to 65% of GLP-1 users discontinue within a year, and why that turns coverage into a sunk cost for employers - What oral GLP-1s like Lilly's Foundayo mean for demand, when most plans still have eligibility rules written for injectables only - How fast a PBM formulary decision can move, using this year's Zepbound to Wegovy switch and back as the case in point - Why 38% of employers already tie GLP-1 coverage to participation in a lifestyle or behavioral program If you're advising employers on GLP-1 coverage, this is where the conversation is heading